- Previous Close
6.90 - Open
6.90 - Bid 6.75 x 40000
- Ask 8.78 x 40000
- Day's Range
6.90 - 6.90 - 52 Week Range
6.61 - 14.25 - Volume
720 - Avg. Volume
198 - Market Cap (intraday)
891.915M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
11.22 - EPS (TTM)
0.68 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.
www.neurenpharma.comRecent News: NURPF
View MorePerformance Overview: NURPF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NURPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NURPF
View MoreValuation Measures
Market Cap
878.78M
Enterprise Value
739.01M
Trailing P/E
11.26
Forward P/E
71.94
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.50
Price/Book (mrq)
4.34
Enterprise Value/Revenue
5.51
Enterprise Value/EBITDA
6.69
Financial Highlights
Profitability and Income Statement
Profit Margin
65.51%
Return on Assets (ttm)
34.05%
Return on Equity (ttm)
49.92%
Revenue (ttm)
216.83M
Net Income Avi to Common (ttm)
142.04M
Diluted EPS (ttm)
0.68
Balance Sheet and Cash Flow
Total Cash (mrq)
222.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.25M